Background: Immunotherapy is a well-established therapeutic approach for treatment of IgE-mediated allergic diseases. It's the only modality that targets the definite cause of allergy, blocks the pathophysiologic aspect of the disease and possibly prevents the development of a new sensitization. Objective: The aim of this work is evaluation of the response of allergic airway diseases to allergen specific immunotherapy. Patients and methods: We enrolled 50 patients with allergic airway diseasesreceiving subcutaneous immunotherapy (SCIT)shots and 30 control patients on pharmacotherapy. The study evaluated clinical assessment of allergic symptoms, medication used and laboratory markers (including specific and total IgE and eosinophil count) before and after 2 years of immunotherapy. Results: Our results showed that there was a significant decrease in total and specific IgE and eosinophil count after SCIT. Also, SCIT effectively reduced the allergic symptoms and the need for medication. Conclusion: Subcutaneous immunotherapy could alleviate allergic symptoms and reduce airway inflammation in allergic patients.